LinkedIn Icon
April 22-25, 2019 | Boston, MA

Lead Partner

ICON plc is a global provider of clinical development solutions and services to the pharmaceutical, biotechnology and medical device industries. The company specialises in the strategic development, management and analysis of programs that support clinical development. With headquarters in Dublin, Ireland, ICON currently, operates from 84 locations in 38 countries and has approximately 12,300 employees.


Senior Partner

PPD is a leading global contract research organization providing comprehensive, integrated drug development, laboratory  and life cycle management services. Our clients and partners include pharmaceutical, biotechnology, medical device, academic and government organizations. With offices in 47 countries and approximately 20,000 professionals worldwide, PPD applies innovative technologies, therapeutic expertise and a firm commitment to quality to help clients and partners bend the cost and time curve of drug development and optimize value in delivering life-changing therapies to improve health.


Senior Partner

ProSciento is a full scope clinical R&D services provider, exclusively focused on diabetes, NASH and obesity. The company is widely recognized for quality and scientific excellence, an unparalleled methodological toolkit, and extensive experience with virtually all relevant metabolic drug and device classes. Through its scalable R&D services model – combining deep therapeutic area expertise, strategic planning, and operational execution from preclinical to phase III readiness – ProSciento provides highly customized services for its global client base.


Senior Partner

Siemens Healthineers enables healthcare providers worldwide to increase value by empowering them on their journey towards expanding precision medicine, transforming care delivery, improving patient experience and digitalizing healthcare. A leader in medical technology, Siemens Healthineers is constantly innovating its portfolio of products and services in its core areas of diagnostic and therapeutic imaging and in laboratory diagnostics and molecular medicine. Siemens Healthineers is also developing its digital health and enterprise services.


Program Partner

HepQuant-SHUNT, -STAT, and -FLOW are sensitive, reproducible, accurate, and minimally-invasive tests of global liver function and physiology. They target not only the liver but also the portal circulation and generate a Disease Severity Index (DSI), which ranges from 0 (healthy) to 50 (severe liver disease). DSI may be used for measuring severity of liver disease, tracking disease progression, and monitoring treatment effects. HepQuant’s services include study design, training, consultation, Test Kits, and Laboratory Analyses.


Spotlight Partner

CrownBio’s metabolic disease portfolio is a unique continuum of translational platforms that enable our clients to take strategic go/no-go decisions as they progress their therapeutic candidates through various stages of drug development. Our clients engage with these translational platforms, which include rodent and non-human primates, (NHP) to model human liver disease pathologies and use them to predict human efficacy and safety of therapeutic candidates.


Spotlight Partner

Organovo develops dynamic, multi-cellular, and fully-human tissues that closely model native architecture and biology.  With the NovoGen Brioprinter® Platform, the Company designs tissues for use in applications spanning pre-clinical safety testing, disease modeling, and regenerative medicine. Tissues are commercially available through its NovoView™ Service Offering and through strategic partnerships. Organovo’s bioprinted tissues enable mechanistic insights into phenotypes that progress over time and that require multiple cell types in a specific spatial organization, reflecting the true complexity of human biology.


Spotlight Partner

Woodland Biosciences is a science-based preclinical CRO focused on metabolic liver diseases and deadly cancers.  Our science base allows us to go beyond just running your experiment to participating in the optimal model development and analyses based on our experience and know-how. We are small enough to be flexible and responsive to your experimental design and needs. We run metabolic-driven NASH, chemically-induced liver fibrosis and xenografts in liver, pancreas and brain cancers among others.



Hosting Partner

High Point Clinical Trials Center has provided comprehensive (Phase I-III) clinical site services since 2008.  Our 42,000 ftfacility consists of three unique units for the execution of outpatient and inpatient clinical studies.  In addition to Healthy Normal studies, HPCTC focuses on specialty populations such as Metabolic Diseases, NASH, Renal Impairment, Respiratory, CNS, Cardiovascular and Nicotine.


Exhibition Partner

Prometheus is committed to improving lives through the development and commercialization of novel pharmaceutical and diagnostic products that enable physicians to provide greater individualized patient care. We are primarily focused on the detection, diagnosis and treatment of disorders within the fields of gastroenterology and oncology.